Ignite Creation Date:
2025-12-24 @ 12:22 PM
Ignite Modification Date:
2025-12-29 @ 5:51 PM
Study NCT ID:
NCT03586661
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-30
First Post:
2018-07-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Deleterious BRCA1 Gene Mutation | View |
| None | Deleterious BRCA2 Gene Mutation | View |
| None | Endometrial Adenocarcinoma | View |
| None | High Grade Ovarian Serous Adenocarcinoma | View |
| None | Platinum-Resistant Ovarian Carcinoma | View |
| None | Primary Peritoneal High Grade Serous Adenocarcinoma | View |
| None | Progressive Disease | View |
| None | Recurrent Endometrial Carcinoma | View |
| None | Recurrent Fallopian Tube Carcinoma | View |
| None | Recurrent Ovarian Carcinoma | View |
| None | Recurrent Primary Peritoneal Carcinoma | View |
Keywords: